Targeting Cbl-b in cancer immunotherapy

• Published in: Journal for immunotherapy of cancer Vol. 11; no. 2; p. e006007
• Main Authors: Augustin, Ryan C., Bao, Riyue, Luke, Jason J.
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01-02-2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Antigens; Biomarkers; Cancer; Cancer therapies; CD28 Antigens - metabolism; Cells; Clinical trials; CTLA-4 antigen; Cytokines; Cytotoxicity; drug therapy, combination; Genome editing; Humans; Immunotherapy; Ligands; Lymphocytes; Lymphoma; Metabolism; Neoplasms; Proteins; Proto-Oncogene Proteins c-cbl - genetics; Review; therapies, investigational; Tumor Microenvironment; Tumors; therapies, investigational; CTLA-4 antigen; drug therapy, combination; review; immunotherapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2022-006007

Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop resistance. To address this unmet need, efforts across the field are targeting additional coinhibitory receptors, costimulatory proteins, and intracellular mediators that could prevent or bypass anti-PD1 resistance mechanisms. The CD28 costimulatory pathway is necessary for antigen-specific T cell activation, though prior CD28 agonists did not translate successfully to clinic due to toxicity. Casitas B lymphoma-b (Cbl-b) is a downstream, master regulator of both CD28 and CTLA-4 signaling. This E3 ubiquitin ligase regulates both innate and adaptive immune cells, ultimately promoting an immunosuppressive tumor microenvironment (TME) in the absence of CD28 costimulation. Recent advances in pharmaceutical screening and computational biology have enabled the development of novel platforms to target this once ‘undruggable’ protein. These platforms include DNA encoded library screening, allosteric drug targeting, small-interfering RNA inhibition, CRISPR genome editing, and adoptive cell therapy. Both genetic knock-out models and Cbl-b inhibitors have been shown to reverse immunosuppression in the TME, stimulate cytotoxic T cell activity, and promote tumor regression, findings augmented with PD1 blockade in experimental models. In translating Cbl-b inhibitors to clinic, we propose specific gene expression profiles that may identify patient populations most likely to benefit. Overall, novel Cbl-b inhibitors provide antigen-specific immune stimulation and are a promising therapeutic tool in the field of immuno-oncology.